MX2024005430A - Composiciones, formas farmaceuticas y metodos de anticuerpos anti-tau. - Google Patents

Composiciones, formas farmaceuticas y metodos de anticuerpos anti-tau.

Info

Publication number
MX2024005430A
MX2024005430A MX2024005430A MX2024005430A MX2024005430A MX 2024005430 A MX2024005430 A MX 2024005430A MX 2024005430 A MX2024005430 A MX 2024005430A MX 2024005430 A MX2024005430 A MX 2024005430A MX 2024005430 A MX2024005430 A MX 2024005430A
Authority
MX
Mexico
Prior art keywords
methods
dosage forms
antibody compositions
tau antibody
antibody
Prior art date
Application number
MX2024005430A
Other languages
English (en)
Spanish (es)
Inventor
Larisa Reyderman
Kristin Ruth Wildsmith
Sumit Rawal
Jin Zhou
Pau Aceves Baldo
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of MX2024005430A publication Critical patent/MX2024005430A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
MX2024005430A 2021-11-03 2022-11-03 Composiciones, formas farmaceuticas y metodos de anticuerpos anti-tau. MX2024005430A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163275045P 2021-11-03 2021-11-03
US202163290278P 2021-12-16 2021-12-16
US202263316582P 2022-03-04 2022-03-04
US202263316616P 2022-03-04 2022-03-04
PCT/IB2022/060604 WO2023079485A1 (en) 2021-11-03 2022-11-03 Anti-tau antibody compositions, dosage forms, and methods

Publications (1)

Publication Number Publication Date
MX2024005430A true MX2024005430A (es) 2024-05-21

Family

ID=84360026

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024005430A MX2024005430A (es) 2021-11-03 2022-11-03 Composiciones, formas farmaceuticas y metodos de anticuerpos anti-tau.

Country Status (9)

Country Link
US (1) US20260159575A1 (enExample)
EP (1) EP4426336A1 (enExample)
JP (1) JP2024540226A (enExample)
KR (1) KR20240118915A (enExample)
AU (1) AU2022381556A1 (enExample)
CA (1) CA3237660A1 (enExample)
MX (1) MX2024005430A (enExample)
TW (1) TW202334201A (enExample)
WO (1) WO2023079485A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025137359A1 (en) 2023-12-20 2025-06-26 Eisai R&D Management Co., Ltd. Assay methods to identify a disease
CN117946264B (zh) * 2024-03-21 2024-06-04 江西赛基生物技术有限公司 一种抗Tau蛋白单克隆抗体及其应用
WO2026015877A1 (en) 2024-07-12 2026-01-15 Eisai R&D Management Co., Ltd. Fluid biomarker

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016010454A2 (pt) * 2013-11-27 2017-12-05 Ipierian Inc métodos para tratar uma taupatia
EP3551220B1 (en) * 2016-12-07 2025-01-29 Genentech, Inc. Anti-tau antibodies and methods of use
JP6851549B2 (ja) 2017-10-16 2021-03-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗タウ抗体及びその使用
US20240101654A1 (en) * 2020-12-29 2024-03-28 Neurimmune Ag Human anti-tau antibodies

Also Published As

Publication number Publication date
KR20240118915A (ko) 2024-08-05
WO2023079485A1 (en) 2023-05-11
CA3237660A1 (en) 2023-05-11
TW202334201A (zh) 2023-09-01
JP2024540226A (ja) 2024-10-31
EP4426336A1 (en) 2024-09-11
AU2022381556A1 (en) 2024-05-02
US20260159575A1 (en) 2026-06-11

Similar Documents

Publication Publication Date Title
EA201992590A1 (ru) Стабильные композиции антител к рецептору программируемой гибели 1 (pd-1) и способы их применения
WO2021044208A8 (en) Antibody-drug conjugate comprising antibody against human ror1, and use for the same
BR112021023024A2 (pt) Anticorpo contra claudina 18a2 e uso do mesmo
MX2019011117A (es) Anticuerpo b7-h3, fragmento de union a antigeno de los mismos y uso medico de los mismos.
MX2018015393A (es) Anticuerpo lag-3, fragmento de union al antigeno del mismo y aplicacion farmaceutica del mismo.
BR112016030686A2 (pt) anticorpos anti tau humanizados
BR112020016331A8 (pt) Métodos para tratar câncer com anticorpos anti-pd-1
UA118453C2 (uk) Спосіб лікування пухлин у пацієнта
MX2020007406A (es) Anticuerpo pd-l1, fragmento de union al antigeno del mismo y uso farmaceutico del mismo.
ZA202103867B (en) Tubulysins and protein-tubulysin conjugates
PH12023550032A1 (en) Tubulysins and protein-tubulysin conjugates
JOP20220357A1 (ar) ربط أجسام مضادة متعددة الخصوصية مع bcma
EA202191666A1 (ru) Антитела к il-27 и их применение
MX2020010119A (es) Anticuerpo anti-cd27, fragmento de union a antigeno del mismo y uso medico del mismo.
JOP20230017A1 (ar) أجسام مضادة لأميلويد بيتا
CL2017001756A1 (es) Régimen de dosificación para antagonistas de madcam.
EA202091112A1 (ru) Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение
MX2022008471A (es) Anticuerpo anti-angptl3 y uso del mismo.
BR112023017556A2 (pt) Anticorpo contra nkp46 e aplicação do mesmo
AU2018282105A1 (en) Dosing of vibegron for treatment of overactive bladder
EP4424709A3 (en) Dosing regimen for anti-bcma agents
MX2018007925A (es) Anticuerpo pcsk9, fragmento de union al antigeno y aplicacion medica del mismo.
PH12022551810A1 (en) Protein-antiviral compound conjugates
MX2020007222A (es) Metodos para el tratamiento de afecciones inflamatorias de la piel.
CR20220127A (es) Administración de dosis para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1